Clinical Trials on Advanced NSCLC

Total 6701 results

Fujian Cancer Hospital

Not yet recruiting

Almonertinib Plus Metronomic Oral Vinorelbine

NSCLC | EGFR | Third-generation TKI
Lady Davis Institute

Withdrawn

Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients (CH:II)

Metastatic NSCLC

Canada
Kyowa Kirin Korea Co., Ltd.

Terminated

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma | Phase 2 Portion : Small Cell Lung Cancer(SCLC)

Korea, Republic of
Qianfoshan Hospital

Recruiting

Patient's Whole Process Follow-up Management(HOPE-1) (HOPE-1)

Metastatic NSCLC | Locally Advanced Non-Small Cell Lung Cancer

China
AbbVie

Active, not recruiting

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Advanced Solid Tumors Cancer | Non Small Cell Lung Cancer (NSCLC)

United States, Australia, France, Israel, Japan, Korea, Republic of, Spain, Taiwan
BrightPath Biotherapeutics

Terminated

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

Metastatic NSCLC

United States
Institut Claudius Regaud
Merck KGaA, Darmstadt, Germany

Completed

Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer

Locally Advanced Non Small Cell Lung Cancer (NSCLC)

France
Case Comprehensive Cancer Center

Terminated

Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study

Advanced (Stage IV) Non-small Cell Lung Cancer (NSCLC)

United States
Spectrum Pharmaceuticals, Inc

Terminated

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Breast Cancer | NSCLC

United States
Samsung Medical Center

Unknown

Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer

Squamous NSCLC

Korea, Republic of
AstraZeneca

Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC in Routine Practices in Russia (PASSAT)

Unresectable /Inoperable Locally Advanced (Stage II-III) Non-small Cells Lung Cancer (NSCLC)

Russian Federation
Shanghai Chest Hospital

Not yet recruiting

SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

NSCLC, Stage III
Guangzhou Institute of Respiratory Disease

Not yet recruiting

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

Staging IV NSCLC

China
Pfizer

Completed

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

ALK-positive NSCLC

Sweden
Mylan Pharmaceuticals Inc

Completed

MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC

NSCLC Stage IV

Turkey, Taiwan, Vietnam, Croatia, India, Russian Federation, Spain, Hungary, Bosnia and Herzegovina, Ukraine, Poland, Romania, Belarus, Bulgaria, Georgia, Italy, Philippines
Instituto do Cancer do Estado de São Paulo

Unknown

Factors Determining the Prognosis in NSCLC Stage IV (LUPROG)

NSCLC Stage IV

Brazil
Beijing Tsinghua Chang Gung Hospital

Recruiting

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

NSCLC, Stage III

China
Hasselt University
Ziekenhuis Oost-Limburg

Completed

Metabolomics Predict Therapy Response (PROLUNG)

NSCLC, Stage IIIA

Belgium
Fudan University

Unknown

Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy (NSCLC)

NSCLC | Chemoradiotherapy | ctDNA

China
KangLaiTe USA

Terminated

Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer

Stage IV NSCLC

United States
Takeda

Active, not recruiting

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3)

ALK+ Advanced NSCLC

Spain, China, Korea, Republic of, Taiwan, Hong Kong, Thailand, Italy, Romania, United States, Mexico, Croatia, Russian Federation, Argentina, Canada, Germany, France, Austria, Chile, Greece, Sweden
Ariad Pharmaceuticals
Takeda

Active, not recruiting

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2)

ALK-positive Advanced NSCLC

Korea, Republic of, United States, Spain, Taiwan, Canada, Hong Kong, China, Sweden, Australia, Italy, Japan, Germany, Netherlands, France, Austria
Shanghai Kechow Pharma, Inc.

Terminated

Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC

Nsclc

China
Instituto Oncológico Dr Rosell
Turning Point Therapeutics, Inc.

Recruiting

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM)

Nsclc

Spain
PTS International Inc.

Completed

A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction

Nsclc

China
Indiana University

Recruiting

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

NSCLC, Stage III

United States
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC

ALK-positive NSCLC

China
Microbio Co Ltd

Recruiting

Safety and Potential Efficacy of MS-20 In Combination With Pembrolizumab for the Treatment of NSCLC

NSCLC Stage IV

Taiwan
Vastra Gotaland Region
AstraZeneca

Recruiting

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) (ASTEROID)

NSCLC, Stage I

Finland, Norway, Sweden
The Netherlands Cancer Institute
Bristol-Myers Squibb

Terminated

Early Response Evaluation in NSCLC Patients Treated With Immunotherapy

NSCLC, Stage IV

Netherlands
Intergroupe Francophone de Cancerologie Thoracique
Amgen

Active, not recruiting

RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC (LungKG12Ci)

Nsclc | KRAS P.G12C

France
Fudan University

Unknown

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC (PCA)

NSCLC Stage IV

China
The First Affiliated Hospital of Guangzhou Medical...

Unknown

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

NSCLC | EGFR Mutation

China
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Spain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
Takeda

Completed

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

ALK-positive Advanced NSCLC

Japan
University Hospital, Strasbourg, France

Not yet recruiting

High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors With Functional Vascularization (TUMOVASC)

NSCLC

France
Shenzhen People's Hospital

Unknown

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC (AFLC)

NSCLC | Apatinib | EGFR-TKI

China
Shenzhen People's Hospital

Unknown

To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma (RCTACSCNSCLC)

NSCLC | EGFR

China
Amsterdam UMC, location VUmc

Completed

Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies (OptiMal)

Colorectum Advanced Malignancies | Breast Advanced Malignancies | Prostate Advanced Malignancies

Netherlands
Genzyme, a Sanofi Company

Completed

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

United States, Czech Republic, Hungary
Radboud University Medical Center

Completed

Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy

NSCLC | Locally Advanced Non-Small Cell Lung Cancer

Netherlands
Eli Lilly and Company

Completed

Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.

Hungary, Germany, Austria, Spain, Sweden
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer | NSCLC, Stage III | Nsclc | NSCLC Stage II

United States
Lung Cancer Group Cologne

Terminated

FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)

NSCLC | Lung Cancer | NSCLC Stage IV | Squamous Cell Lung Cancer | Pulmonary Neoplasm

Germany
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Squamous NSCLC

China
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
Newsoara Biopharma Co., Ltd.

Not yet recruiting

HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

NSCLC Stage IV
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
University Hospital, Essen

Recruiting

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA)

NSCLC, Stage III

Germany
Zhejiang Genfleet Therapeutics Co., Ltd.

Active, not recruiting

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

NSCLC, Stage III

China

Clinical Trials on Advanced NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations